Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia

Trial Profile

Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs MVA CMV (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2016 According to City of Hope and Helocyte media release, data from this study was published in Blood, the journal of the American Society of Hematology.
    • 19 Oct 2016 Results published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top